Filtered By:
Source: European Heart Journal
Condition: Atrial Fibrillation

This page shows you your search results in order of relevance. This is page number 4.

Order by Relevance | Date

Total 120 results found since Jan 2013.

Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark
Conclusion</div>Since 2010, more incident AF patients in Denmark were initiated on OAC therapy with predominant NOAC prescription. The increase was pronounced among females, among patients at high risk of stroke, and among older patients.</span>
Source: European Heart Journal - January 20, 2017 Category: Cardiology Source Type: research

Left atrial appendage occlusion: rationale, evidence, devices, and patient selection
<span class="paragraphSection">Atrial fibrillation (AF) is a worldwide epidemic associated with significant morbidity and mortality, often due to disabling or fatal thromboembolic stroke. Oral anticoagulation is highly effective at preventing ischaemic stroke and improving all-cause survival in patients with non-valvular AF. Despite the efficacy of oral anticoagulation, many patients are not treated due to either absolute or perceived contraindications to therapy, including bleeding. Left atrial appendage (LAA) closure has emerged as a mechanical alternative to pharmacologic stroke prevention. Initial and mid-term cl...
Source: European Heart Journal - September 14, 2016 Category: Cardiology Source Type: research

Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden
Conclusion Dabigatran is a cost-effective treatment in Sweden, as its incremental cost-effectiveness ratio is below the normally accepted willingness to pay limit.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Davidson, T., Husberg, M., Janzon, M., Oldgren, J., Levin, L.-A. Tags: Arrhythmia/electrophysiology Source Type: research

Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)
Conclusion Betrixaban was well tolerated and had similar or lower rates of bleeding compared with well-controlled warfarin in patients with AF at risk for stroke.
Source: European Heart Journal - May 21, 2013 Category: Cardiology Authors: Connolly, S. J., Eikelboom, J., Dorian, P., Hohnloser, S. H., Gretler, D. D., Sinha, U., Ezekowitz, M. D. Tags: Arrhythmia/electrophysiology Source Type: research

Antihypertensive treatment and risk of atrial fibrillation: a nationwide study
Conclusion Use of ACEis and ARBs compared with β-blockers and diuretics associates with a reduced risk of atrial fibrillation, but not stroke, within the limitations of a retrospective study reporting associations. This suggests that controlling activation of the renin-angiotensin system in addition to controlling blood pressure is associated with a reduced risk of atrial fibrillation.
Source: European Heart Journal - May 7, 2014 Category: Cardiology Authors: Marott, S. C. W., Nielsen, S. F., Benn, M., Nordestgaard, B. G. Tags: Hypertension Source Type: research

Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48
Conclusions In a contemporary AF population, LA structure and function were increasingly abnormal with a greater electrical burden of AF and higher stroke risk estimated by the CHADS2 score. Moreover, LA dysfunction was present despite normal LA size and sinus rhythm, suggesting that the assessment of LA function may add important incremental information in the evaluation of AF patients. Clinical Trial Registration: http://www.clinicaltrials.gov; ID = NCT00781391.
Source: European Heart Journal - June 7, 2014 Category: Cardiology Authors: Gupta, D. K., Shah, A. M., Giugliano, R. P., Ruff, C. T., Antman, E. M., Grip, L. T., Deenadayalu, N., Hoffman, E., Patel, I., Shi, M., Mercuri, M., Mitrovic, V., Braunwald, E., Solomon, S. D., for the Effective aNticoaGulation with factor xA next GEnerat Tags: Atrial fibrillation Source Type: research

Long working hours as a risk factor for atrial fibrillation: a multi-cohort study
ConclusionIndividuals who worked long hours were more likely to develop atrial fibrillation than those working standard hours.
Source: European Heart Journal - July 13, 2017 Category: Cardiology Source Type: research

Atrial fibrillation as a risk factor for cognitive decline and dementia
ConclusionIn adults aged 45 –85 years AF is associated with accelerated cognitive decline and higher risk of dementia even at ages when AF incidence is low. At least in part, this was explained by incident cardiovascular disease in patients with AF.
Source: European Heart Journal - April 29, 2017 Category: Cardiology Source Type: research

Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial
ConclusionUninterrupted edoxaban therapy represents an alternative to uninterrupted VKA treatment in patients undergoing AF ablation.
Source: European Heart Journal - April 11, 2019 Category: Cardiology Source Type: research

The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
Conclusion The CHA2DS2-VASc score reclassifies 26% of patients with a CHADS2 score of 1 to a low annual risk of SSE of 1%. This risk seems low enough to consider withholding anticoagulant treatment.
Source: European Heart Journal - January 14, 2013 Category: Cardiology Authors: Coppens, M., Eikelboom, J. W., Hart, R. G., Yusuf, S., Lip, G. Y. H., Dorian, P., Shestakovska, O., Connolly, S. J. Tags: Arrhythmia/electrophysiology Source Type: research

Biomarkers in atrial fibrillation: a clinical review
Assessment of atrial fibrillation (AF)-associated stroke risk is at present mainly based on clinical risk scores such as CHADS2 and CHA2DS2-VASc, although these scores provide only modest discrimination of risk for individual patients. Biomarkers derived from the blood may help refine risk assessment in AF for stroke outcomes and for mortality. Recent studies of biomarkers in AF have shown that they can substantially improve risk stratification. Cardiac biomarkers, such as troponin and natriuretic peptides, significantly improve risk stratification in addition to current clinical risk stratification models. Similar finding...
Source: European Heart Journal - May 21, 2013 Category: Cardiology Authors: Hijazi, Z., Oldgren, J., Siegbahn, A., Granger, C. B., Wallentin, L. Tags: REVIEW Source Type: research

EHRA Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients will have to learn how to use these drugs effectively and safely in specific clinical situations. This text is an executive summary of a practical guide that the European Heart Rhythm Association (EHRA) has assembled to help physicians in the use of the different NOACs. The full text is being published in EP Europace. Practical answers have been formulated for 15 concrete clinical scenarios: (i) practical start-up and follow-up scheme for ...
Source: European Heart Journal - July 14, 2013 Category: Cardiology Authors: Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., Kirchhof, P. Tags: SPECIAL ARTICLE Source Type: research

CardioPulse Articles * Warfarin increases stroke risk in atrial fibrillation * Aspirin still overprescribed for stroke prevention in atrial fibrillation * Clinical Research in Cardiology: the official journal of the German Cardiac Society (Deutsche Gesellschaft fur Herz-/Kreislaufforschung) * Septic shock in infective endocarditis * Innovation in atrial fibrillation therapy
Source: European Heart Journal - June 7, 2014 Category: Cardiology Tags: CardioPulse Source Type: research

Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial
Conclusion The efficacy and safety of apixaban compared with aspirin is consistent in subgroups of patients who have previously attempted but failed VKA therapy, irrespective of the reason for discontinuation.
Source: European Heart Journal - July 21, 2014 Category: Cardiology Authors: Coppens, M., Synhorst, D., Eikelboom, J. W., Yusuf, S., Shestakovska, O., Connolly, S. J. Tags: Atrial fibrillation Source Type: research

Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry)
Conclusion In this 1-year follow-up analysis of the EORP-AF pilot general registry, we provide data on the first contemporary registry focused on management practices among European cardiologists, conducted since the publication of the new ESC guidelines. Overall OAC use remains high, although persistence with therapy may be problematic. Nonetheless, continued OAC use was more common than in prior reports. Despite the high prescription of OAC, 1-year mortality and morbidity remain high in AF patients, particularly from heart failure and hospitalizations.
Source: European Heart Journal - December 14, 2014 Category: Cardiology Authors: Lip, G. Y. H., Laroche, C., Ioachim, P. M., Rasmussen, L. H., Vitali-Serdoz, L., Petrescu, L., Darabantiu, D., Crijns, H. J. G. M., Kirchhof, P., Vardas, P., Tavazzi, L., Maggioni, A. P., Boriani, G. Tags: Fast Track ESC Clinical Trial and Registry Update Source Type: research